StreetInsider.com News Articles

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics

Mon, 29 Dec 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin® technology platform, jointly announce the termination of their collaboration agreement signed in May 2024.
Based on both parties’ commitment to scientific excellence and resource optimization, OPM and Navigo have mutually agreed to end this specific collaboration. As a reminder, the partnership between Navigo and OPM was intended

Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics

Mon, 29 Dec 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin® technology platform, jointly announce the termination of their collaboration agreement signed in May 2024.
Based on both parties’ commitment to scientific excellence and resource optimization, OPM and Navigo have mutually agreed to end this specific collaboration. As a reminder, the partnership between Navigo and OPM was intended

Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics

Mon, 29 Dec 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin® technology platform, jointly announce the termination of their collaboration agreement signed in May 2024.
Based on both parties’ commitment to scientific excellence and resource optimization, OPM and Navigo have mutually agreed to end this specific collaboration. As a reminder, the partnership between Navigo and OPM was intended

Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics

Mon, 29 Dec 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin® technology platform, jointly announce the termination of their collaboration agreement signed in May 2024.
Based on both parties’ commitment to scientific excellence and resource optimization, OPM and Navigo have mutually agreed to end this specific collaboration. As a reminder, the partnership between Navigo and OPM was intended

Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics

Mon, 29 Dec 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin® technology platform, jointly announce the termination of their collaboration agreement signed in May 2024.
Based on both parties’ commitment to scientific excellence and resource optimization, OPM and Navigo have mutually agreed to end this specific collaboration. As a reminder, the partnership between Navigo and OPM was intended

Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics

Mon, 29 Dec 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin® technology platform, jointly announce the termination of their collaboration agreement signed in May 2024.
Based on both parties’ commitment to scientific excellence and resource optimization, OPM and Navigo have mutually agreed to end this specific collaboration. As a reminder, the partnership between Navigo and OPM was intended

OPM Obtains Development Grants From the Bourgogne Franche-Comté Region

Tue, 14 Oct 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces that it has received notification of the allocation of an investment grant from the Bourgogne Franche-Comté Region.
This grant, totaling €250,000, is part of a regional support program for innovative SMEs developing strategic technological expertise to boost competitiveness and growth in the region. This program aims to support companies in the region with high-impact technological projects by promoting innovation, value creation, and regional roots at different stages of their development.
The

OPM Obtains Development Grants From the Bourgogne Franche-Comté Region

Tue, 14 Oct 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces that it has received notification of the allocation of an investment grant from the Bourgogne Franche-Comté Region.
This grant, totaling €250,000, is part of a regional support program for innovative SMEs developing strategic technological expertise to boost competitiveness and growth in the region. This program aims to support companies in the region with high-impact technological projects by promoting innovation, value creation, and regional roots at different stages of their development.
The

OPM Obtains Development Grants From the Bourgogne Franche-Comté Region

Tue, 14 Oct 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces that it has received notification of the allocation of an investment grant from the Bourgogne Franche-Comté Region.
This grant, totaling €250,000, is part of a regional support program for innovative SMEs developing strategic technological expertise to boost competitiveness and growth in the region. This program aims to support companies in the region with high-impact technological projects by promoting innovation, value creation, and regional roots at different stages of their development.
The